OTINUS-X NASAL DROPS Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
OTINUS-X NASAL DROPS
Xylometazoline IP 0.1% w/v
OTINUS-X NASAL DROPS (Xylometazoline IP 0.1% w/v) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in OTINUS-X NASAL DROPS deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store in a cool and dry place. Use within 1 month after opening container.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
OTINUS-X NASAL DROPS features Xylometazoline IP 0.1% w/v prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Endorsed by attending medical offic for OTINUS-X NASAL DROPS
OTINUS-X NASAL DROPS has been endorsed by attending medical officers for dependable recovery, offering predictable therapeutic action that doctors in our territory rely upon daily. Sturdy outer cartons and individual pack serialization facilitate seamless inventory scanning. Continues to be a key prescription driver in our PCD pharma franchise portfolio.
Questions Regarding OTINUS-X NASAL DROPS
What is the therapeutic indication and composition of OTINUS-X NASAL DROPS?
OTINUS-X NASAL DROPS contains Xylometazoline IP 0.1% w/v indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for OTINUS-X NASAL DROPS?
OTINUS-X NASAL DROPS is supplied in tamper-evident 5ml / 10ml Precision Dropper Bottle with Tamper Ring, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for OTINUS-X NASAL DROPS?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for OTINUS-X NASAL DROPS along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
OTINUS-X NASAL DROPS is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Drops
View all Drops →
OTINUS-S NASAL DROPS
Sodium Chloride 0.65% w/v + Benzalkonium Chloride Solution 0.02% v/v
